Theratechnologies annoncera ses résultats du troisième trimestre de l’exercice financier de 2023
18 sept. 2023 16h15 HE
|
Theratechnologies
MONTRÉAL, 18 sept. 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique axée sur le développement...
Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis
13 sept. 2023 09h10 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer
11 sept. 2023 07h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S.
29 août 2023 08h01 HE
|
Ocean Biomedical, Inc.
Ocean’s small molecule candidate significantly controls fibrosis progression in idiopathic pulmonary fibrosis (IPF) and Hermansky-Pudlak Syndrome (HPS) in multiple testing models. Patent granted for...
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
23 août 2023 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with...
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results
08 août 2023 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
Resmetirom new drug application (NDA) submitted to the U.S. Food and Drug AdministrationNASH disease education and market development activities expand to support potential first-to-market launch in...
A Call for Help from Physician Specialists on the Frontline Treating MASLD/MASH
18 juil. 2023 09h29 HE
|
Spherix Global Insights
Exton, Pennsylvania, July 18, 2023 (GLOBE NEWSWIRE) -- Data from the Centers for Disease Control & Prevention (CDC) suggests just over seventy percent of American adults are overweight,...
Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
17 juil. 2023 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease
11 juil. 2023 07h00 HE
|
CytoSorbents
PRINCETON, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Non-alcoholic Steatohepatitis Therapeutics Market to Grow at a CAGR of 13.6% during the 2022 to 2031 Forecast Period: TMR Study
07 juil. 2023 07h00 HE
|
Transparency Market Research
Wilmington, Delaware, United States, July 07, 2023 (GLOBE NEWSWIRE) -- The global non-alcoholic steatohepatitis therapeutics market stood at US$ 10.1 billion in 2021 and the global non-alcoholic...